Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population of the industrialized world. AMD is a progressive degenerative disease affecting the central area of the retina, responsible for distinct vision. Vision loss arises from aberrant new vessel growth which causes the accumulation of blood or fluid within the retina's thickness and eventually leads to permanent scarring. The two major forms of AMD are exudative, or neovascular or "wet", and non-exudative, or "dry". Vascular endothelial growth factor (VEGF) represents the key modulator of the angiogenetic process and is involved in the pathophysiology of AMD. Anti VEGF therapies are used to treat wet-AMD. After diagnosis and explanations of the practionner, the patients and their close relatives have still frequently many questions about the intravitreal injections, the prognosis, the risk of visual impairment, etc. Few teams have studied the modalities of diagnosis announcement and the understanding of the patients on the disease course. The aim of this study is to evaluate the feelings after the AMD diagnosis announcement as well as the understanding of the possibilities of treatment and the clinical surveillance.
Study Type
OBSERVATIONAL
Enrollment
250
Marciano Joelle
Créteil, Creteil, France
Description of the patient's feelings
A questionnaire with a list of different feelings: anxiety, distress, relief, resigned, guilty, etc. is proposed to the patient after AMD diagnosis. they can also explain their feelings by themselves.
Time frame: up to 1 month after diagnosis
score of general satisfaction
the patient will score their satisfaction on a numeric scale from 0 (not satisfied at all) to 10 (extremely satisfied)
Time frame: up to 1 month after diagnosis
score on a comprehension quiz on AMD
Time frame: up to 1 month after diagnosis
Score on a composite score evaluating the clarity of medical explanations
Time frame: up to 1 month after diagnosis
Score on a composite score evaluating the clarity of medical explanations
Time frame: between 6 months and 1 year of follow-up
score of satisfaction of announcement conditions
Time frame: up to 1 month after diagnosis
score of satisfaction of announcement conditions
Time frame: between 6 months and 1 year of follow-up
score of satisfactions regarding the clarity of the disease course and treatment explanations
Time frame: between 6 months and 1 year of follow-up
Score on the anxiety PHQ9 questionnaire
Time frame: between 6 months and 1 year of follow-up
Score on the anxiety GAD7 questionnaire
Time frame: between 6 months and 1 year of follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.